Candel Therapeutics

United States
Needham, Massachusetts, United States, 02494

Company profile

Candel Therapeutics company profile

Candel develops cancer immunotherapies designed to improve the lives of cancer patients and their families. The company's immunotherapies focus on preventing the recurrence and progression of cancer with low toxicity level which is well suited for the treatment of less aggressive or slower growing cancers such as newly diagnosed prostate cancer, enabling physicians to ensure improved outcomes for their patients and help them recover faster.

Business identity

Contact email
[email protected]
Phone number
6179165445
Operating status
Active
Company type
For Profit
Employee range
11-50 employees
Revenue range
$50,000+
Founded
1999-01-01, Year

Headquarters

Postal code
02494
Country code
US
Continent
North America

Capital profile

Funding and company signals

Funding stage
IPO
Funding rounds
10
Total equity funding
$244.2M
Last funding
Post IPO Debt / $50M / 2025-10-14
Last equity funding
Post IPO Equity / $15M
Investors
9
Lead investors
5
Founders
1
Articles
169
Exited on
2021-07-27

Founders and investors

Founders

Estuardo Aguilar-Cordova

Lead investors

National Securities CorporationNorthpond VenturesPBM Capital GroupSilicon Valley BankTrinity Capital

Investors

Massachusetts Life Sciences CenterNorthpond VenturesSands Capital VenturesSilicon Valley BankTrinity Capital